13.09.2024

Deal |

2024

Formo Closes a US$ 61 Million Series B Round

  • HQ: DE

Founded: 2018

  • Series B
  • Sector: Life Science

Investment Raised: USD 61m €

Valuation Remains Undisclosed

Investors: Elevat3 Capital, EQT Ventures, FoodLabs, Grazia Equity, Happiness Capital, Indiposa Investments, Lowercarbon Capital, M Ventures, Rewe Group, Sazaby League, SevenVentures, The Nature Conservancy, Woodline Partners

News Link
08.07.2024

Deal |

2024

SmartCella raises EUR 50 million to accelerate growth and commercialization

  • HQ: SW

Founded: 2014

  • Private Equity Round
  • Sector: Biotechnology, Health Care, Life Science, Medical, Therapeutics

Investment Raised: EUR 50M €

EUR 500M

Valuation

Investors: SEB (Skandinaviska Enskilda Banken), RoosGruppen, Handelsbanken Fonder, Fjarde AP-fonden, AstraZeneca, AMF

News Link
18.10.2023

Deal |

2023

4D Lifetec to Sell 20 Percent Stake to Xlife Sciences for $25.9M

  • HQ: CH

Founded: 2019

  • Series C
  • Sector: Life Science

Investment Raised: CHF 23M €

Valuation Remains Undisclosed

Investors: Xlife Sciences AG (https://www.xlifesciences.ch/)

News Link
30.05.2023

Deal |

2023

eXmoor pharma Closes USD 35M Series A Funding

  • HQ: UK

Founded: 2004

  • Series A
  • Sector: Life Science

Investment Raised: USD 35M €

Valuation Remains Undisclosed

Investors: Kineticos Ventures (https://www.kineticos.com/) MVM Life Science Partners (https://mvm.com/)

News Link
15.05.2023

Deal |

2023

Oxford biotech OMass Therapeutics raises £10m

  • HQ: UK

Founded: 2016

  • Series B
  • Sector: Life Science

Investment Raised: GBP 10M €

Valuation Remains Undisclosed

Investors: British Patient Capital (https://www.britishpatientcapital.co.uk/)

News Link
24.10.2022

Deal |

2022

Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography Workflow

  • HQ: DE

Founded: 2020

  • Series B
  • Sector: Life Science

Investment Raised: USD 71M €

Valuation Remains Undisclosed

Investors: Alafi Capital (https://www.linkedin.com/company/alafi-capital-corp/about/) EDBI (https://edbi.com/home/) High-Tech Grunderfonds (https://www.htgf.de/de/) John Shoffner NRW.BANK (https://www.nrwbank.de/de/) Patient Square Capital (https://patientsquarecapital.com/) PS Capital (https://pscapitalpartners.com/)

News Link
01.09.2022

Deal |

2022

Zur Rose Group successfully raises CHF 44 million as Capital Increase by way of an accelerated book building process

  • HQ: CH

Founded: 1993

  • Post-IPO Equity
  • Sector: Life Science

Investment Raised: CHF 44M €

Valuation Remains Undisclosed

Investors: Remains Undisclosed

News Link
01.08.2022

Deal of the Week |

Calendar Week # 32 |

2022

Vector Biopharma closes $30M series A round to support new gene therapy vector

  • HQ: CH

Founded: 2021

  • Series A
  • Sector: Life Science

Investment Raised: USD 30M €

Valuation Remains Undisclosed

Investors: Versant Ventures (https://www.versantventures.com/)

News Link
28.09.2021

Deal |

2021

Lifebit raises USD 60M to make vital biomedical data securely accessible for life changing research worldwide

  • HQ: UK

Founded: 2017

  • Series B
  • Sector: Life Science

Investment Raised: USD 60M €

Valuation Remains Undisclosed

Investors: Tiger Global Management (https://www.tigerglobal.com/) Pentech Ventures (https://pentech.vc/) Eurazeo (https://www.eurazeo.com/en) Beacon Capital (https://www.beaconcapital.com/)

News Link